Albert R Collison

Title: Albert R. Collison: Innovator in Blocked Lectins

Introduction

Albert R. Collison is a notable inventor based in Boston, MA. He has made significant contributions to the field of biochemistry, particularly in the development of methods and materials related to lectins. His innovative work has led to the creation of a patent that addresses critical challenges in cell targeting and treatment.

Latest Patents

Collison holds a patent for "Blocked lectins; methods and affinity support for making the same." This patent describes an activated affinity ligand that comprises a ligand with a region that binds to lectin binding sites and a reactive group that covalently links the ligand to the lectin. The invention includes a blocked lectin that consists of one or more affinity ligands linked to a lectin, effectively blocking its binding sites. Additionally, it details a cell-binding agent-blocked lectin conjugate and methods for preparing this conjugate. The patent also outlines a method for selectively killing cell populations while minimizing cytotoxicity to non-selected cells, using the described conjugate.

Career Highlights

Collison is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance research in cancer treatment. His work is pivotal in developing targeted therapies that utilize lectins to improve treatment efficacy.

Collaborations

He has collaborated with esteemed colleagues such as Walter A. Blattler and Charles F. Scott, Jr. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Albert R. Collison's contributions to the field of biochemistry, particularly through his patent on blocked lectins, demonstrate his commitment to advancing medical science. His work at the Dana-Farber Cancer Institute Inc. continues to impact cancer treatment methodologies significantly.